Home » Newsletters » BioWorld Science

BioWorld Science

March 17, 2010

View Archived Issues

Clinical data on Gardasil reported at EUROGIN meeting

Takeda claims new GPR52 receptor agonists for schizophrenia

Merck & Co. patents new CGRP receptor antagonists

Genentech discovers novel IAP inhibitors for treatment of cancer

Advenchen claims new tyrosine kinase inhibitors for cancer therapy

Allergan discloses novel prostanoid EP2 receptor agonists

Merck & Co. reports clinical data on mometasone furoate/formoterol fumarate in asthma

Patient enrollment ongoing in phase II trial of pioglitazone in intracerebral hemorrhage

Ipsen initiates dosing in two phase II studies of BIM-23A760 in cancer

Viron reports preclinical results on VT-346 in arthritis

LLS and Forma to develop new therapies for diffuse large B-cell lymphoma

Dynavax expects earlier BLA submission for Heplisav

Medicago and MOU partner to commercially develop influenza vaccines in Japan

DARPA awards funds to Fraunhofer USA CMB for development H1N1 vaccine

Lilly to acquire worldwide license to Acrux's testosterone solution Axiron

Nuvo begins enrollment in phase II trial of WF-10 in allergic rhinitis

DEF-201 active against Western equine encephalitis virus, a potential biothreat

Hantavirus DNA vaccines safe and well tolerated in phase I study

bioMerieux launches screening tool for vancomycin-resistant enterocci in U.S.

Tekmira and Pfizer collaborate on stable nucleic acid-lipid particle technology

Genentech submits Actemra sBLA to FDA for additional RA indication

Third dose group treated in PCI Biotech's phase I/II trial of Amphinex in cancer

Iverson Genetic Diagnostics to evaluate gene-based testing before warfarin anticoagulation therapy

FDA to review primary data from ACCORD lipid trial

Lundbeck initiates phase II trial of desmoteplase for ischemic stroke in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...